Latest Equity Incentives News

Caprice Resources has appointed CEO Luke Cox as Managing Director, underscoring confidence in his leadership to drive exploration and development in the Murchison Goldfields and West Arunta regions.

AVITA Medical has appointed Board Chairman Cary Vance as Interim CEO following Jim Corbett's departure, while preliminary third-quarter revenue is expected to reach approximately $17 million.

Vanadium Resources Limited has appointed mining entrepreneur Nick Diack as CEO to spearhead the transition of its Steelpoortdrift Vanadium Project towards near-term production, signaling a strategic shift backed by strong industry expertise and performance-linked incentives.

Newmont Corporation announces the retirement of CEO Tom Palmer at year-end 2025, with President and COO Natascha Viljoen stepping up as the first female CEO in the company’s century-long history.

Bravura Solutions has appointed Colin Greenhill as its new Group CEO, effective 1 January 2026, following a comprehensive global search. Greenhill brings over 15 years of leadership experience in financial services software, signaling a strategic step forward for the company.

Frontier Digital Ventures announces key leadership changes with Patrick Grove stepping in as Executive Chairman and a planned CEO transition by November 2025.

Leo Lithium has announced a significant $330 million return to shareholders in 2025, following the termination of its asset acquisition strategy and a decision to monetise remaining assets.

Camplify Holdings has responded to ASX concerns over a delayed director interest notice, revealing internal process failures and promising tighter compliance measures.

Dotz Nano Limited reported a reduced half-year loss and significant progress in its Direct Air Capture technology, while navigating funding uncertainties with key investors.

Uscom Limited reported a 25% decline in revenue to $3.16 million and a 59% increase in net loss to $3.3 million for FY25, reflecting significant global headwinds. Despite setbacks, the company advanced new product approvals and secured funding to navigate ongoing challenges.

Syntara Limited reported a significantly reduced loss for FY2025, driven by clinical progress and capital raises, while advancing its lead drug amsulostat with FDA Fast Track designation. The company also navigates ongoing payment disputes following the sale of its mannitol respiratory business.

Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.